{"id":499308,"date":"2021-05-27T07:33:06","date_gmt":"2021-05-27T11:33:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-hold-corporate-update-friday-june-11th\/"},"modified":"2021-05-27T07:33:06","modified_gmt":"2021-05-27T11:33:06","slug":"aptose-to-hold-corporate-update-friday-june-11th","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-hold-corporate-update-friday-june-11th\/","title":{"rendered":"Aptose to Hold Corporate Update Friday, June 11th"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Clinical Updates for Luxeptinib in AML &amp; B-cell Cancers and for APTO-253 in AML &amp; MDS<\/em><br \/>\n        \n      <\/p>\n<p align=\"center\">\n        <em>Poster Presentations for CG-806 and APTO-253 are Scheduled for June 11th at\u00a0<\/em><br \/>\n        <em>EHA2021 Virtual Congress<\/em>\n      <\/p>\n<p align=\"justify\">SAN DIEGO and TORONTO, May  27, 2021  (GLOBE NEWSWIRE) &#8212; Aptose Biosciences Inc. (\u201cAptose\u201d) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will provide a corporate update for the investment community on Friday, June 11<sup>th<\/sup>, at 8:00 AM ET, in conjunction with participation at the EHA2021 Virtual Congress. The event will include an up-to-date review of clinical data available for Aptose\u2019s clinical programs: luxeptinib (CG-806), Aptose\u2019s oral, first-in-class FLT3 and BTK kinase inhibitor in two Phase 1 a\/b trials, one in patients with relapsed or refractory acute myeloid leukemia (AML) and another in patients with relapsed or refractory B cell malignancies; and APTO-253, a first-in-class small molecule MYC repressor in a Phase 1 a\/b trial in patients with relapsed or refractory AML or high risk myelodysplastic syndromes (MDS).<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <u>Aptose Corporate Update Details<\/u><br \/>\n        <\/strong>\ufeff<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"3\">\n            <strong>Date &amp; Time:<\/strong> Friday, June 11th, 8:00 AM ET<strong><br \/><\/strong>\u00a0<\/td>\n<\/tr>\n<tr>\n<td colspan=\"3\">\n            <strong>Participant Webcast Link<\/strong>:\u00a0<a href=\"http:\/\/public.viavid.com\/index.php?id=145004\" rel=\"nofollow noopener\" target=\"_blank\">LINK<\/a>\u00a0<strong><br \/><\/strong>\u00a0<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\">\n            <strong>Participant Dial-in:\u00a0<\/p>\n<p><\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:3%;width:3%;min-width:3%\">\u00a0<\/td>\n<td style=\"max-width:10%;width:10%;min-width:10%\">\n            <strong>Toll Free:<\/p>\n<p><\/strong>\n          <\/td>\n<td style=\"max-width:87%;width:87%;min-width:87%\">1-877-407-9039<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\n            <strong>Toll\/International<\/strong>:<\/p>\n<\/td>\n<td>1-201-689-8470<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\n            <strong>Conference ID:<\/strong>\u00a0<\/td>\n<td>13719895<\/td>\n<\/tr>\n<\/table>\n<p>The slides will be available on Aptose\u2019s website\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aghtDZaz_G1zHuNGzj-ES6qFaQ3VF_4NKIS1miI5tDd16HZ-Xwez1shbYy3hW8uYGg1FrkDVHtm7WIx5hF8S8tar0h9UcE-HeIOB_ZHR8hQ=\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>\u00a0and a recording of the presentation will be archived shortly after the conclusion of the event.<\/p>\n<p>Early clinical data for luxeptinib (CG-806) and APTO-253 also will be presented in posters at the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8lDgd6qGO6nSajlDHx5bc7LlGzHHUmUsBJlIVt_cVtkI11CBKdXcHZhOuVtsGJQh6ZT0C2dNPxmOBDXOl5W_brvUabAQrNeWAFm36e8XNmdgSOI5XplmgHM8h3-4YSsM9Rs9wBfgvR4lCdXB_8ZoEg==\" rel=\"nofollow noopener\" target=\"_blank\">EHA2021 Virtual Congress<\/a>, to be held virtually June 9 &#8211; 17, 2021. All e-posters will be made available in the Virtual Congress platform on Friday, June 11 at 09:00 CEST \/ 03:00 ET. The posters also will be available on the presentations page of Aptose website <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=A3Xb0ysBLGTYpzbfN7cIqTbSEgmV44oHECdXUf2yjWuI482WKnesf2o42QV6OjsfWo35zRpAON2HtxumYVysloIWCe81W0GJC5dP-cs7fno=\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>.<\/p>\n<p>\n        <strong><br \/>\n          <u>Poster Presentation Details<\/u><br \/>\n        <\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:12%;width:12%;min-width:12%\">\n            <strong>Title:<\/strong>\n          <\/td>\n<td style=\"max-width:88%;width:88%;min-width:88%\">A Phase 1a\/b dose escalation study of the mutation agnostic BTK\/FLT3 inhibitor luxeptinib (CG-806) in patients with relapsed or refractory B cell malignancies<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Topic:<\/strong>\n          <\/td>\n<td>Chronic lymphocytic leukemia and related disorders &#8211; Clinical<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Final Abstract Code: <\/strong>\n          <\/td>\n<td>EP643<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Poster Date &amp; Time:<\/strong>\n          <\/td>\n<td>Friday, June 11 at 09:00 CEST<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Title: <\/strong>\n          <\/td>\n<td>A Phase 1a\/b dose escalation study of the MYC repressor APTO-253 in patients with relapsed or refractory AML or high-risk MDS<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Topic:<\/strong>\n          <\/td>\n<td>Acute myeloid leukemia &#8211; Clinical<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Final Abstract Code:<\/strong>\n          <\/td>\n<td>EP452<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Poster Date &amp; Time:<\/strong>\n          <\/td>\n<td>Friday, June 11 at 09:00 CEST<\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong><br \/>\n          <u>Abstract Only<\/u><br \/>\n        <\/strong><br \/>\n        \n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:12%;width:12%;min-width:12%\">\n            <strong>Title:<\/strong>\n          <\/td>\n<td style=\"max-width:88%;width:88%;min-width:88%\">A Phase 1a\/b dose escalation study of the mutation agnostic BTK\/FLT3 inhibitor luxeptinib (CG-806) in patients with relapsed or refractory acute myeloid leukemia<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Topic:<\/strong>\n          <\/td>\n<td>Acute myeloid leukemia &#8211; Clinical<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Final Abstract Code:<\/strong>\n          <\/td>\n<td>PB1391<\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong>About Aptose<\/strong><br \/>\n        \n      <\/p>\n<p>Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company&#8217;s small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies. The first investigational product, luxeptinib, an oral, first-in-class mutation-agnostic FLT3\/BTK kinase inhibitor, is in a Phase 1a\/b trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies, and in a separate Phase 1a\/b trial in patients with relapsed or refractory acute myeloid leukemia (AML). The second investigational product, APTO-253, the only known clinical stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1a\/b clinical trial for the treatment of patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS).<\/p>\n<p align=\"justify\">For further information, please contact:<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:30%;width:30%;min-width:30%\">Aptose Biosciences Inc. <\/td>\n<td style=\"max-width:70%;width:70%;min-width:70%\">LifeSci Advisors, LLC<\/td>\n<\/tr>\n<tr>\n<td>Susan Pietropaolo\u00a0<\/td>\n<td>Dan Ferry, Managing Director<\/td>\n<\/tr>\n<tr>\n<td>Investor Relations<\/td>\n<td>617-535-7746<\/td>\n<\/tr>\n<tr>\n<td>201-923-2049<\/td>\n<td>\n            <a href=\"mailto:Daniel@LifeSciAdvisors.com\" rel=\"nofollow noopener\" target=\"_blank\">Daniel@LifeSciAdvisors.com<\/a>\n          <\/td>\n<\/tr>\n<tr>\n<td>\n            <a href=\"mailto:spietropaolo@aptose.com\" rel=\"nofollow noopener\" target=\"_blank\">spietropaolo@aptose.com<\/a>\n          <\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDAzMSM0MjA0NTY0IzIwMjcyODA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/580d8c0c-95a5-4c19-aa6f-17ea26d126b8\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Clinical Updates for Luxeptinib in AML &amp; B-cell Cancers and for APTO-253 in AML &amp; MDS Poster Presentations for CG-806 and APTO-253 are Scheduled for June 11th at\u00a0 EHA2021 Virtual Congress SAN DIEGO and TORONTO, May 27, 2021 (GLOBE NEWSWIRE) &#8212; Aptose Biosciences Inc. (\u201cAptose\u201d) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will provide a corporate update for the investment community on Friday, June 11th, at 8:00 AM ET, in conjunction with participation at the EHA2021 Virtual Congress. The event will include an up-to-date review of clinical data available for Aptose\u2019s clinical programs: luxeptinib (CG-806), Aptose\u2019s oral, first-in-class FLT3 and BTK kinase inhibitor &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-hold-corporate-update-friday-june-11th\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aptose to Hold Corporate Update Friday, June 11th&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-499308","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aptose to Hold Corporate Update Friday, June 11th - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-hold-corporate-update-friday-june-11th\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aptose to Hold Corporate Update Friday, June 11th - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Clinical Updates for Luxeptinib in AML &amp; B-cell Cancers and for APTO-253 in AML &amp; MDS Poster Presentations for CG-806 and APTO-253 are Scheduled for June 11th at\u00a0 EHA2021 Virtual Congress SAN DIEGO and TORONTO, May 27, 2021 (GLOBE NEWSWIRE) &#8212; Aptose Biosciences Inc. (\u201cAptose\u201d) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will provide a corporate update for the investment community on Friday, June 11th, at 8:00 AM ET, in conjunction with participation at the EHA2021 Virtual Congress. The event will include an up-to-date review of clinical data available for Aptose\u2019s clinical programs: luxeptinib (CG-806), Aptose\u2019s oral, first-in-class FLT3 and BTK kinase inhibitor &hellip; Continue reading &quot;Aptose to Hold Corporate Update Friday, June 11th&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-hold-corporate-update-friday-june-11th\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-27T11:33:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDAzMSM0MjA0NTY0IzIwMjcyODA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-to-hold-corporate-update-friday-june-11th\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-to-hold-corporate-update-friday-june-11th\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aptose to Hold Corporate Update Friday, June 11th\",\"datePublished\":\"2021-05-27T11:33:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-to-hold-corporate-update-friday-june-11th\\\/\"},\"wordCount\":632,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-to-hold-corporate-update-friday-june-11th\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NDAzMSM0MjA0NTY0IzIwMjcyODA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-to-hold-corporate-update-friday-june-11th\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-to-hold-corporate-update-friday-june-11th\\\/\",\"name\":\"Aptose to Hold Corporate Update Friday, June 11th - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-to-hold-corporate-update-friday-june-11th\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-to-hold-corporate-update-friday-june-11th\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NDAzMSM0MjA0NTY0IzIwMjcyODA=\",\"datePublished\":\"2021-05-27T11:33:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-to-hold-corporate-update-friday-june-11th\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-to-hold-corporate-update-friday-june-11th\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-to-hold-corporate-update-friday-june-11th\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NDAzMSM0MjA0NTY0IzIwMjcyODA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NDAzMSM0MjA0NTY0IzIwMjcyODA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-to-hold-corporate-update-friday-june-11th\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aptose to Hold Corporate Update Friday, June 11th\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aptose to Hold Corporate Update Friday, June 11th - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-hold-corporate-update-friday-june-11th\/","og_locale":"en_US","og_type":"article","og_title":"Aptose to Hold Corporate Update Friday, June 11th - Market Newsdesk","og_description":"Clinical Updates for Luxeptinib in AML &amp; B-cell Cancers and for APTO-253 in AML &amp; MDS Poster Presentations for CG-806 and APTO-253 are Scheduled for June 11th at\u00a0 EHA2021 Virtual Congress SAN DIEGO and TORONTO, May 27, 2021 (GLOBE NEWSWIRE) &#8212; Aptose Biosciences Inc. (\u201cAptose\u201d) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will provide a corporate update for the investment community on Friday, June 11th, at 8:00 AM ET, in conjunction with participation at the EHA2021 Virtual Congress. The event will include an up-to-date review of clinical data available for Aptose\u2019s clinical programs: luxeptinib (CG-806), Aptose\u2019s oral, first-in-class FLT3 and BTK kinase inhibitor &hellip; Continue reading \"Aptose to Hold Corporate Update Friday, June 11th\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-hold-corporate-update-friday-june-11th\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-27T11:33:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDAzMSM0MjA0NTY0IzIwMjcyODA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-hold-corporate-update-friday-june-11th\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-hold-corporate-update-friday-june-11th\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aptose to Hold Corporate Update Friday, June 11th","datePublished":"2021-05-27T11:33:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-hold-corporate-update-friday-june-11th\/"},"wordCount":632,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-hold-corporate-update-friday-june-11th\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDAzMSM0MjA0NTY0IzIwMjcyODA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-hold-corporate-update-friday-june-11th\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-hold-corporate-update-friday-june-11th\/","name":"Aptose to Hold Corporate Update Friday, June 11th - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-hold-corporate-update-friday-june-11th\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-hold-corporate-update-friday-june-11th\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDAzMSM0MjA0NTY0IzIwMjcyODA=","datePublished":"2021-05-27T11:33:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-hold-corporate-update-friday-june-11th\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-hold-corporate-update-friday-june-11th\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-hold-corporate-update-friday-june-11th\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDAzMSM0MjA0NTY0IzIwMjcyODA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDAzMSM0MjA0NTY0IzIwMjcyODA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-hold-corporate-update-friday-june-11th\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aptose to Hold Corporate Update Friday, June 11th"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/499308","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=499308"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/499308\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=499308"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=499308"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=499308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}